Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 14, 2009 - Issue 3
Submit an article Journal homepage
98
Views
7
CrossRef citations to date
0
Altmetric
Reviews

Emerging drugs for prostate cancer

Kashif Siddiqui Chief, University of Toronto, Sunnybrook Health Sciences Centre, Division of Urology, 2075 Bayview Ave. #MG408 Toronto, Ontario M4N 3M5, Canada +1 416 480 4673; +1 416 480 6121; [email protected]
&
Laurence H Klotz Chief, University of Toronto, Sunnybrook Health Sciences Centre, Division of Urology, 2075 Bayview Ave. #MG408 Toronto, Ontario M4N 3M5, Canada +1 416 480 4673; +1 416 480 6121; [email protected]
Pages 455-470 | Published online: 04 Aug 2009

Bibliography

  • National Cancer Institute of Canada, Canadian Cancer Statistics 2008. Available from: www.cancer.ca
  • US National Cancer Institute, Cancer Statistics 2008. Available from: www.cancer.gov/statistics
  • Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. Eur J Cancer 2001;37(8):4-66
  • Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival prevalence and mortality. BJU Int 2002;90(2):162-73
  • Jemal A, Tewari RC, Murray T, et al. American Cancer Society. Cancer statistics 2004. CA Cancer J Clin 2004;54(1):8-29
  • American Cancer Society, Cancer Statistics 2005. Available from: www.cancer.org
  • Miller BA, Chu KC, Hankey BF, Ries LA. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the US. Cancer Causes Control 2008;19(3):227-56
  • Scardino PT. The Gordon Wilson lecture: natural history and treatment of early stage prostate cancer. Trans Am Clin Climatol Assoc 2000;111:201-41
  • American Cancer Society, Cancer Statistics 2007. Available from: www.cancer.org
  • Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer 2004;101(10):2371-490
  • Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101(1):3-27
  • Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combining histological grading and clinical staging. J Urol 1974;111(1):58-64
  • Stark JR, Perner S, Stampfer MJ, et al. Gleason score and lethal prostate cancer: Does 3+4=4+3? JCO online May 11, 2009. [Epub ahead of print]
  • Carter BS, Beatty TH, Steinberg GD, et al. Mendelion inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992;89(8):3367-71
  • Bratt O. Hereditary prostate cancer: clinical aspects. J Urol 2002;168:906-13
  • Shelly MD, Kumar S, Wilt T, et al. A systematic review and meta-analysis of randomized trials of neo-adjuvant hormone therapy for localized and locally advanced prostate carcinoma. Cancer Treat Rev 2009;35:9-17
  • Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12 month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102:1531-38
  • Klotz L. Maximal androgen blockade for advanced prostate cancer. Best Pract Res Clin Endocrinol Metab 2008;22(2):331-40
  • Van Poppel H, Tombal B, de le Rosette JJ et al. Degarelix: a novel GnRH receptor blocker-Results from a 1 year, multicentre, randomized phase II dosage finding study in the treatment of prostate cancer. Eur Urol 2008;54:805-15
  • McLeod D, Zinner N, Tomera K, et al. A phase III, multicentre, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58:756-61
  • Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:213-22
  • Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172:1314
  • Kramer BS, Hagerty KL, Justman S, et al. Use of 5α-reductase inhibitors for prostate cancer chemoprevention: ASCO/AUA2008 Clinical Practice Guidelines. J Urol 2009;181:1642-57
  • Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
  • Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
  • Garmey EG, Sartor O, Halabi S, Vogelzang NJ. Second-line chemotherapy for advanced castration resistant prostate cancer [Review]. Clin Adv Hematol Oncol 2008;6(2):118-22, 127-32
  • Michels J, Montemurro T, Murray N, et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with castration resistant prostate cancer: does sequence matter? Cancer 2006;106(5):1041-6
  • Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143(4):747-52
  • Catalona WJ, Partin AW, Slawin KM, et al. Use of percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;20:279(19):1542-47
  • Stephan C, Jung K, Lein M, et al. PSA and other tissue kallikreins for prostate cancer detection. Eur J Can 2007;43:1918-26
  • Kwiatkowski MK, Recker F, Piironen T, et al. In prostatism patients the ratio of human glandular kallikrein to fPSA improves the discrimination between prostate cancer and benigh hyperplasia within the diagnostic gray zone of PSA 4-10ng/ml. Urology 1998;52(3):360-5
  • Haese A, Becker C, Steuber T, et al. hK2: a potential serum marker for predicting the organ confined versus nonorgan confined growth of prostate cancer. J Urol 2000;163:1491-7
  • Nakamura T, Scorilas A, Stephan C, et al. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign hyperplasia. Cancer Res 2003;63:6543-6
  • Wosikowski K, Lamphere L, Unteregger G. Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 2007;60:589-600
  • Latif T, Wood L, Connell C, et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer. Invest New Drugs 2005;23:79-84
  • Jones S, Hainsworth J, Burris AH, et al. Phase I study of JM-216 in combination with paclitaxel in patients with advanced malignancies. Invest New Drugs 2002;20:55-61
  • Sternberg CN, Whelan P, Hetherington J, et al. Genitourinary Tract Group of the EORTC. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with castration resistant prostate cancer. Multicenter Study. RC Trial Oncol 2005;68(1):2-9
  • Oh WK, Tay MH, Huang J. Is there a role for Platinum Chemotherapy in treatment of patients with CRPCA. Cancer 2007;109(3):477-86
  • Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22(10):2015-25
  • Donovan D, Vahdat LT. Epothilones: clinical update and future directions. Oncology 2008;22(4):408-16
  • Galsky MD, Small EJ, Oh WK, et al. Multi-instituitional randomized phase II trial of the epothilone B analog ixabepilone with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23:1439-46
  • Hussain M, Tangen CM, Lara PN Jr, et al. Ixabepilone (epothilone B analogue) is active in chemotherapy-naïve patients with hormone refractory prostate cancer. SWOG S0111. J Clin Oncol 2005;23:8724-9
  • Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory castration resistant prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110(3):556-63
  • Titus MA, Schell MJ, Lih FB, et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-7
  • Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006;12:1665-71
  • Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen receptor signaling axis. J Clin Oncol 2005;23:8253-61
  • Koivisto P, Kononen J, Palmberg T, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57(2):314-9
  • Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharm 2008;8:440-8
  • O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17 α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317-25
  • Attard G, Reid A, Yap T, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate confirms that castration-resistatnt prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26(28):4563-71
  • Reid A, Attard G, Molife R, et al. Selective CYP17 inhibition with abiraterone acetate results in a high response rate in castration resistant prostate cancer confirming the continued importance of targeting androgen receptor signaling. In Proceedings of 2008 Genitourinary Cancers Symposium. Abstract 50
  • Ryan C, Rosenberg J, Lin A, et al. Small E. Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17 alpha hydroxylase C17, 20 lyase inhibitor in castration resistant prostate cancer. ASCO 2008 Genitourinary Cancers Symposium. Abstract 157
  • Danilla D, Rathkopf D, Fleisher M, et al. Preliminary Phase II results of abiraterone acetate in patients with castration-resistant metastatic prostate cancer after failure of docetaxel based chemotherapy. In Proceedings 2008 Genitourinary Cancer Symposium. Abstract 3
  • Mendieta MAEP, Negri M, Jagusch C, et al. Synthesis, biologic evaluation and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer. J Med Chem 2008;51:5009-18
  • Ryan CJ, Weinberg V, Rosenberg J, et al. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol 2007;178:2372-6
  • Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025-33
  • Yap TA, Carden CP, Attard G, deBono JS. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol 2008;8:449-57
  • Andriole GL, Humphrey P, Ray P, et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. Multicenter Study. Randomized Controlled Trial. J Urol 2004;172(3):915-9
  • Shah SK, Trump DL, Sartor O, et al. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol 2009;181(2):621-6
  • Melcher A, Gough M, Todryk S, et al. Apoptosis or necrosis for tumor immunotherapy: what's in a name? J Mol Med 1997;77:824
  • Bander NH, Yao D, Liu H, et al. MHC Class I and II expression in prostate carcinoma and modulation by interferon-alpha and gamma. Prostate 1997;33:233
  • Sanda MG, Restifo NP, Walsh JC, et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995;87:280
  • Moon C, Park JC, Chae YK, et al. Current status of experimental therapeutics for prostate cancer. Cancer Lett 2008;266(2):116-34
  • Small EJ, Schellhammer PF, Higano CS, et al. Placebo controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19):3089-94
  • Simons JW, Carducci MA, Mikhak B, et al. Phase I/II trial of an allogenic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res 2006;12:3394-401
  • Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogenic cancer cellular immunotherapy. The GVAX vaccine for prostate cancer. Urol Oncol 2006;24:419-24
  • Patel P, Ashdown D, James N. Is gene therapy the answer for prostate cancer? Prostate Cancer Prostatic Dis 2004;7(1):S14-9
  • Sanda MG, Smith DC, Charles LG, et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate specific immune response in androgen-modulated human prostate cancer. Urology 1999;53:260-66
  • Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22(11):2122-32
  • Sangha R, North S. L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. Expert Opin Biol Ther 2007;7(11):1723-30
  • Carducci MA, Slawin KM, Solit DB. Emerging Therapies for Prostate Cancer. Chapter 6 Report to the Nation (2004), Prostate Cancer Foundation. Available from: www.prostatecancerfoundation.org
  • Small E. Monoclonal Antibody therapy for prostate cancer: Finally a reality? J Clin Oncol 2004;22(13):2515-6
  • Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of PSMA also react with tumor vascular endothelium. Cancer Res 1997;57:3629-34
  • Bander NH, Nanus DM, Milowsky MI, et al. Targeted systemic therapy of prostate cancer with a monoclonal antibody prostate-membrane antigen. Semin Oncol 2003;30:667-77
  • Nanus DM, Milowsky MI, Kostakoglu L, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate-specific membrane antigen. J Urol 2003;170(2):S84-8
  • Milowsky MI, Nanus DM, Kostakoglu L, et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22(13):2522-31
  • Small EJ, Tchekmedyian NS, Rini BI, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with castration resistant prostate cancer. Clin Cancer Res 2007;13(6):1810-5
  • Fong L, Rini B, Kavanaugh B, et al. CTLA-4 blockade-based immunotherapy for prostate cancer. Proc Am Soc Clin Oncol 2004;23:185
  • Drake CG. Immunotherapy for metastatic prostate cancer. Urol Oncol 2008;26:438-44
  • Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;174:539-46
  • Arlen PM, Gulley JL, Todd N, et al. Antiandrogen, vaccine, and combination therapy in patients with non-metastatic hormone refractory prostate cancer. J Urol 2005;174:539-46
  • Arlen PM, Gulley JL, Parker C, et al. A randomized Phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12:1260-9
  • Armstrong AJ, Carducci MA. New drugs in prostate cancer. Curr Opin Urol 2006;16:138-45
  • Corcoran NM, Costello AJ, Hovens CM. Interfering with cell-survival signalling as a treatment strategy for prostate cancer. BJU Int 2006;97:1149
  • McMenamin ME, Soung P, Parera S, et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59:4291-96
  • Ayala G, Thompson T, Yang G, et al. High levels of phosphorylated form of akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004;10:6572-78
  • Zellweger T, Ninck C, Bloch M, et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005;113(4):619-28
  • Canil CM, Moore MJ, Winquist E, et al. Randomized Phase II study of 2 doses of geftinib in CRPCA. J Clin Oncol 2005;23(3):455-60
  • Ziada A, Barqawi A, Glode LM, et al. The use of trastuzumab in the treatment of CRPCA: phase II trial. Prostate 2004;60:332-7
  • Gravis G, Goncalves A, Bladou F, et al. A Phase II study of erlotinib in advanced prostate cancer. Ann Oncol 2008;19(9):1624-8
  • Nelson J. Endothelin Inhibition: novel therapy for prostate cancer. J Urol 2003;170:S65-68
  • Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944
  • Nelson J, Bagnato A, Battistini B, et al. The endothelin axis:emerging role in cancer. Nat Rev Cancer 2003;3:110-6
  • Gohji K, Kitazawa S, Tamada H, et al. Expression of endothelin receptor is associated with prostate cancer progression. J Urol 2001;165:1033-6
  • Opgenorth TJ, Adler AL, Caldazilla SV, et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 1996;276:473-81
  • Carducci MA, Nelson JB, Bowling MK, et al. Atrasentan, an endothelin-receptor antagonist, in men with symptomatic hormone refrasctory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 2002;20:2171
  • Carducci MA, Saad F, Abrahamsson PA, et al. Atrasentan Phase III Study Group Institutions. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic castration resistant prostate cancer. Cancer 2007;110(9):1959-66
  • Nelson JB, Love W, Chin JL, et al. Atrasentan Phase 3 Study Group. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, castration resistant prostate cancer. Cancer 2008;113(9):2478-87
  • Morris CD, Rose A, Curwen J, et al. Specific inhibition of the endothelin A receptor with ZD4054 clinical and pre-clinical evidence. Brit J Cancer 2005;92:2148-52
  • Lalich M, McNeel DG, Wilding G, Liu G. Endothelin receptor antagonisyts in cancer therapy. Cancer Investig 2007;25:785-94
  • Miyamoto H, Altuwaijri S, Cai Y, et al. Inhibition of the Akt, cycloxegenase-2 and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy:potential therapeutic approaches for prostate cancer. Mol Carcinog 2005;44(1):1-10
  • Mathew P, Thall PF, Bucana CD, et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 2007;13(19):5816-24
  • Mathew P, Thall PF, Jones D, et al. PDGFR inhibitor imatinib mesylate and docetaxel: a modular Phase I trial in androgen-independent prostate cancer. J Clin Oncol 2004;22:3323-9
  • Cardones AR, Banez LL. VEGF inhibitors in cancer therapy. Curr Pharm Des 2006;12(3):387-94
  • Duque JL, Loughlin KR, Adam RM, et al. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics (Sao Paulo, Brazil) 2008;61(5):401-8
  • Li H, Kantoff PW, Ma J, et al. Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2005;14(6):1557-61
  • Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Cancer 2008;8(8):579-91
  • Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New Eng J Med 2007;357(26):2666-76
  • Picus J, Halabi S, Rini B, et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer [abstract 1578]. Proc Am Soc Clin Oncol 2003;22:393
  • Sonpavde G, Hutson TE. New approaches in CRPCA. Am J Clin Oncol 2006;29:196-201
  • Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22(13):2532-9
  • Dreicer R, Petrylak D, Agus D, et al. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 2007;13(4):1208-15
  • Huanh XU, Xiaoping Z, Benyamin F, Olumi A. Novel targeted pro-apoptotic agents for the treatment of prostate cancer. J Urol 2007;178:1846-54
  • Gao S, Wang H, Lee P, et al. Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J Mol Endocrinol 2006;36:463
  • Marini P, Denzinger D, Schiller S, et al. Combined treatment of colorectal tumors with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006;25:5145-54
  • McDonnell TJ, Troncoso P, Brisbay S, et al. Expression of bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-44
  • Feng P, Li T, Guan Z, et al. The involvement of bax in zinc-induced mitochodrial apoptogenesis in malignant prostate cells. Mol Cancer 2008;7:25
  • Leung S, Miyake H, Zellweger T, et al. Synergistic chemosensitization and inhibition of progression to androgen-independence by anti-sense Bcl-2 oligodeoxynucleotide and paclitxel in the LnCaP prostate tumor model. Int J Cancer 2001;91:846-50
  • Chi KN, Gleave ME, Klasa R, et al. A Phase I dose finding study of combined treatment with an antisense bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone refractory prostate cancer. Clin Can Res 2001;7:3920-7
  • Meng Y, Tang W, Dai Y, et al. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 2008;7(7):2192-202
  • Tan TT, Degenhardt K, Nelson DA, et al. Key roles of BIM driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005;7:227
  • Van Veldhuizen PJ, Taylor SA, Williamson S, Drees BM. Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength. J Urol 2000;163(1):187-90
  • Huncharek M, Muscat J, Kupelnick B. Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr Cancer 2008;60(4):421-41
  • Getzenberg RH, Light BW, Lapco PE, et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997;50:999-1006
  • Hershberger PA, Yu MD, Modzekewski RA, et al. Calciterol enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001;7:1043-51
  • Beer TM. ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int 2005;96(4):508-13
  • Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25(6):669-74
  • Beer TM, Eilers KM, Garzotto M, et al. Weekly high dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003;21:123-8
  • Hussain T, Gupta S, Mukhtar H, et al. Cyclooxegenase-2 and prostate carcinogenesis. Cancer Lett 2003;191:125-35
  • Pruthi RS, Derksen JE, Moore D, et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 2006;12(7 Pt 1):2172-7
  • Smith MR, Manola J, Kaufman DS, et al. Celecoxib versus placebo for men with prostate cancer and a rising serum PSA after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006;24:2723-8
  • Taneja SS, Smith MR, Dalton JT, et al. Toremifene–a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs 2006;15(3):293-305
  • Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008;179(1):152-5
  • Simoneau AR, Gerner EW, Nagle R, et al. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2008;17(2):292-9
  • Gupta S. Prostate cancer chemoprevention: current status and future prospects. Toxicol Appl Pharmacol 2007;224(3):369-76
  • The Alpha-Tocpherol Beta Carotene (ATBC) Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330(15):1029-35
  • Clark LC, Coombs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA 1996;276:1957-63
  • Lippman SM, Klein EA, Goodman PJ, et al. Effect of Selenium and Vitamin E on risk of prostate cancer. The Selenium and Viatamin E cancer Prevention Trial (SELECT). JAMA 2009;301(1):39-51
  • Saad F. Zoledronic Acid significantly reduces pathologis fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Pros Can 2002;1(3):145-52
  • Sartor O. Overview of samarium 153 lexidronam in the treatment of painful metasttic bone disease. Rev Urol 2004;6(10):S3-10
  • Dizeyi N, Konrad L, Bjartell A. Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol 2002;7:91-8
  • Stangelberger A, Schally AV, Djavan B. New treatment approaches for prostate cancer based on peptide analogues. Eur Urol 2008;53:890-900

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.